AVI BioPharma to Host Analyst & Investor Breakfast Meeting
September 08 2008 - 9:30AM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII) announced today that it will
host a breakfast meeting for analysts, brokers, investors and the
Company's shareholders on Wednesday, September 10, 2008, from 7:30
a.m. to 10:30 a.m. EDT at the Harvard Club of New York City. AVI's
senior management team will be joined by Dr. Francesco Muntoni,
Professor of Pediatric Neurology, University College London
Institute of Child Health, and Ben Johnson, Engineering Manager at
Global Therapeutics, a Cook Medical Company and partner with AVI in
the development of the new GTX drug-eluting stent platform
utilizing AVI-5126 for the reduction of cardiovascular restenosis.
The breakfast session and presentations will provide an
opportunity to learn about the status of the Company's clinical
programs and the latest advances in its third-generation antisense
technology as well as to participate in an interactive discussion
about AVI's RNA-based therapeutic platform. The presentation will
include specific updates on the Company's clinical programs in
Duchenne Muscular Dystrophy (DMD), cardiovascular restenosis and
AVI's biodefense collaboration with USAMRIID targeting Ebola,
Marburg and other pathogens.
Speakers from AVI include: Dr. Leslie Hudson, President and CEO;
David Boyle, CFO; Dr. Patrick Iversen, SVP of Strategic Alliances;
and Dr. Ryszard Kole, SVP of Discovery Research.
Space is limited, so those wishing to attend and who have not
already received an invitation should respond at RSVP@avibio.com.
For those unable to attend, a recording and slide presentation will
be available after the meeting on the Company's website:
www.avibio.com.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
RNA-based drugs using the company's expanded portfolio of
proprietary antisense compounds (PMOs). The company's technology
applications leverage distinct mechanisms of action in a range of
genetic diseases, genetic disorders and the genetic code of
disease-causing organisms. The emerging field of directed
alternative RNA splicing represents AVI's newest application of the
company's core antisense technology. The Company believes that
functional attributes of this approach may include correcting
genetic defects (RNA mutations, which AVI believes could produce
promising treatments for Duchenne muscular dystrophy), coding for
novel soluble receptors (an exciting and novel approach which could
have application in the treatment of inflammatory diseases such as
rheumatoid arthritis), and the reduction in activity of immune
modulators in disease states (currently being applied to IL-10).
AVI's RNA-based drug programs also include blocking mRNA
translation. In AVI's biodefense program, this application has been
successful against the single-stranded RNA viruses Ebola Zaire and
Marburg Musoke in non-human primates and may have value against
other viral targets such as HCV, Dengue, Junin, influenza and RSV
viruses. This application also will be evaluated in the clinic for
the treatment of cardiovascular restenosis by our partner, Cook
Medical. More information about AVI is available at
www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements that are not historical facts
contained in this release are forward-looking statements that
involve risks and uncertainties, including, but not limited to, the
results of research and development efforts, the results of
preclinical and clinical testing, the effect of regulation by the
FDA and other agencies, the impact of competitive products, product
development, commercialization and technological difficulties, and
other risks detailed in the company's Securities and Exchange
Commission filings.
AVI Press and Investor Contact: Michael Hubbard Email Contact
Director of Corporate Communications (503) 227-0554
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024